Enzalutamide [ENZ5]
Enzalutamide for the treatment of patients with hormone-relapsed (castrate- resistant) metastatic prostate cancer with disease progression during or following treatment with docetaxel-containing chemotherapy where the following criteria have been met:
- This application is being made by and the first cycle of systemic anti-cancer therapy with enzalutamide will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.
- This patient either has a proven histological or cytological diagnosis of adenocarcinoma of the prostate or has presented with a clinical picture consistent with metastatic prostate cancer with both widespread bone metastases radiologically typical of prostate cancer and a serum PSA of ≥50 ng/mL.
- This patient has hormone-relapsed (castration-resistant) metastatic prostate cancer.
- The patient has been treated with docetaxel-containing chemotherapy and has progressed during or following treatment.
- One of the following applies to this patient as regards any previous use of 2nd generation receptor inhibitors (such as enzalutamide, darolutamide or apalutamide) or CYP17 enzyme inhibitors (such as abiraterone). Please enter below as to which scenario applies to this patient:
- the patient has not previously received any treatment with enzalutamide or darolutamide or apalutamide or abiraterone or
- the patient has previously received abiraterone for this same post-chemotherapy indication in hormone-relapsed (castrate-resistant) prostate cancer but it was stopped within 3 months of it starting due to dose-limiting toxicity and in the clear absence of disease progression
- The patient has an ECOG performance status (PS) of 0 or 1 or 2.
- Enzalutamide is to be continued until disease progression or unacceptable toxicity or patient choice to stop treatment.
- A formal medical review as to how enzalutamide is being tolerated and whether treatment with enzalutamide should continue or not will be scheduled to occur at least by the start of the third 4-weekly cycle of treatment.
- Where a treatment break of more than 6 weeks beyond the expected 4-weekly cycle length is needed, I will complete a treatment break approval form to restart treatment, including indicating as appropriate if the patient had an extended break because of COVID 19.
- Enzalutamide is to be otherwise used as set out in its Summary of Product Characteristics.
NHS funded From: 21 October 2014
Additional information
Current Form Version
Note
The data on this page was produced using version 1.361 of the CDF list, downloaded from an archive of NHS England’s website on 08 May 2025 at 22:10.
If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.